Disc Medicine received a Complete Response Letter from the FDA on February 13, 2026, rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. Following this, the company's stock price fell 22%. Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit to recover investor losses, offering compensation without upfront fees. Investors who purchased Disc Medicine securities may join the lawsuit by contacting the firm.
Nike's Chief Operating Officer, Alagirisamy Venkatesh, has sold 3,671 shares of the company's stock. Insider sales like this can indicate personal financial decisions or portfolio adjustments but do not necessarily reflect the company's overall healt...
Canadian mortgage lender Pineapple Financial has migrated over $1 billion worth of residential mortgage records onto the Injective blockchain, making Injective the largest blockchain for tokenized real estate. The migration includes 2,079 detailed mo...
Entergy is well-positioned to convert new industrial demand into regulated earnings growth, supported by strong capital investment plans and regulatory approvals. The company’s premium valuation is justified by visible customer commitments, though ex...
Clearpool, an institutional lending protocol with over $965 million in loans originated, proposes migrating fully to the XRP Ledger. This includes swapping its CPOOL token for a new CLEAR token and launching RLUSD-denominated credit products backed b...
Primerica, Inc. reported robust growth in its investment and savings segment, which now accounts for 42% of its revenue, with a 21% increase in revenue and 31% rise in pre-tax profit in Q2 2026. Although the company faces declining sales in new term ...
